PE-22-28 vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | PE-22-28 | SHLP2 |
|---|---|---|
| Mechanism | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Very limited human data. Primarily studied in animal models for safety and efficacy. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |
What They Have in Common
Both PE-22-28 and SHLP2 are commonly used for: